Research and Markets: The Stem Cell Market Outlook

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/b79257/the_stem_cell_mark) has announced the addition of the "The Stem Cell Market Outlook" report to their offering.

This report covers the commercialization of stem cells (primarily derived from adult tissues) which are transplanted into patients to improve the function of diseased/damaged tissues/organs. Six indications are covered in detail. Sales forecasts are estimated in the US and five major European markets (5EU), which include France, Germany, Italy, Spain and the UK.

Features and Benefits:

• Identify potential growth markets with sales forecasts by indication and expected timing of market entry.
• Compare the different business models for stem cell therapies.
• Evaluate which novel products offer the greatest potential clinical advances over the next several years and why.
• Assess potential clinical advances and how they address current unmet needs.
• Understand the drivers and resistors of the stem cell market.

Highlights:

• Six indications were prioritized based on likely commercial potential and adoption into clinical practice: acute myocardial infarction, heart failure, critical limb ischemia, amyotrophic lateral sclerosis, spinal cord injury and ischemic stroke.
• Companies are developing first generation therapies primarily based on ex vivo expanded allogeneic or autologous bone marrow derived stem cells. Recently, a second generation of products has entered clinical development, which may build on the efficacy of first generation products.
• The greatest potential revenues are forecast in diseases or conditions with significant mortality or morbidity and limited treatment options, for which autologous bone marrow mononuclear cells (BMMNCs) may not be applicable or ineffective and lower patient numbers can be offset by higher prices.

Your Key Questions Answered:

• What is the future commercial value of stem cell therapies?
• Which products are likely to be reimbursed and what price could be charged?
• Which indications offer the greatest sales potential?
• What are the competitive risks to commercialization and how can companies develop profitable business models?
• Which companies are attractive for investment?

Key Topics Covered:

Executive Summary

• Market overview
• Acute myocardial infarction
• Heart failure
• Critical limb ischemia
• Central nervous system disorders
• Other indications
• Business models and market forecasts

Market Overview

• Summary
• Introduction
• Market definition
• Stem cell types
• Adult stem cells
• Embryonic stem cells
• Clinical landscape
• Regulation
• European Union
• Japan
• India
• China
• Industry overview
• Market value
• Licensing and merger activity
• Conclusions

Acute myocardial infaction

• Summary
• Introduction
• Clinical review
• Pipeline analysis
• Allogeneic products
• Cell processing devices
• Market potential
• Calculation of addressable population
• Market adoption scenario
• Future outlook

Heart Failure

• Summary
• Introduction
• Clinical review
• Ongoing trials using BMMNCs or MSCs
• Other stem cells types
• Mechanism of action
• Pipeline analysis
• Autologous products
• Allogeneic products
• Market size
• Future outlook

Critical limb ischemia

• Summary
• Introduction
• Clinical review
• Pipeline analysis
• Autologous products
• Allogeneic products
• Cell processing devices
• Market size
• Future outlook

Central Nervous System Disorders

• Summary
• Introduction
• Amyotrophic lateral sclerosis
• Spinal cord injury
• Ischemic stroke
• Future outlook

Other Indications

• Summary
• Introduction
• Graft versus host disease
• Solid organ transplants
• Diabetes mellitus
• Chronic obstructive pulmonary disease
• Inflammatory bowel disease
• Acute kidney injury
• Alzheimer's disease
• Parkinson's disease
• Multiple sclerosis

Business Models and Market Forecasts

• Summary
• Introduction
• Key success factors
• Acute versus elective conditions
• Regulatory considerations
• Stem cell quality
• Manufacturing process
• Clinical trial design
• Business models
• Allogeneic product models
• Autologous product models
• Device based models
• Pricing and reimbursement
• Sales forecasts to 2025
• Future outlook

For more information visit http://www.researchandmarkets.com/research/b79257/the_stem_cell_mark

Source: Business Insights